๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Changchun
Clinical trial register · China

Clinical Trials in Changchun, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca102 The First Hospital of Jilin University47 Hoffmann-La Roche31 Janssen Research & Development, LLC30 Eli Lilly and Company23
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Changchun

641 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
NCT07781150Obesity, Overweight, Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I
Tongji Hospital
Phase 2
128
Zhengzhou, Wuhan, Changchun, Hangzhou, Shanghai, Tianjin
2026-11-01
Not yet open
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors
NCT07774611Advanced Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2
180
Chongqing, Fuzhou, Guanzhou, Chengde, Haerbin, Xinxiang, Changsha, Changchun
2026-09-22
Not yet open
Treatment Strategy for Patients With RA-ILD
NCT07643038Rheumatoid Arthritis Associated Interstitial Lung Disease
Chinese SLE Treatment And Research Group
Phase 4
204
Luoyang, Beijing, Changchun, Chongqing, Dalian, Handan, Hangzhou, Hefei
2026-09-20
Not yet open
A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus
NCT07751848Lupus Erythematosus, Systemic
AstraZeneca
Phase 3
417
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangdong Province, Guangzhou, Hangzhou
2026-09-04
Not yet open
HP007 Monotherapy for Relapsed or Refractory Advanced Solid Tumors
NCT07800936Solid Tumors
Parr Biotechnology (Hebei) Co., Ltd.
Phase 1
44
Changchun
2026-09-01
Not yet open
SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
NCT07830238B-cell Acute Lymphoblastic Leukemia
Shanghai Simnova Biotechnology Co.,Ltd.
Phase EARLY_PHASE1
28
Changchun
2026-09
Recruiting
Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment
NCT07809802Hepatic Impairment (HI)
Betta Pharmaceuticals Co., Ltd.
Phase 1
36
Changchun
2026-09
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
AstraZeneca
Phase 3
6,950
Baoding, Beijing, Bozhou, Changchun, Changde, Changsha, Chengdu, Chifeng
2026-08-24
Recruiting
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
NCT07776509Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
AstraZeneca
Phase 3
500
Beijing, Changchun, Chengdu, Guangzhou, Huzhou, Nanjing, Ningbo
2026-08-24
Not yet open
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2
AstraZeneca
Phase 3
1,500
Beijing, Cangzhou, Changchun, Chengdu, Danyang, Ganzhou, Guangzhou, Huizhou
2026-08-21
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993Chronic Kidney Disease
AstraZeneca
Phase 3
7,000
Baoding, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chenzhou, Chongqing
2026-08-21
Recruiting
Safety and Short-term Outcomes of Modular Robotic System for Siewert II/III Gastroesophageal Junction Cancer
NCT07790809Siewert Type II/III Gastroesophageal Junction Adenocarcinoma
The First Hospital of Jilin University
Not applicable
25
Changchun
2026-08-20
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
AstraZeneca
Phase 3
2,500
Beijing, Cangzhou, Changchun, Changsha, Chengdu, Danyang, Ganzhou, Guiyang
2026-08-19
Recruiting
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
NCT07700667Esophageal Squamous Cell Carcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Changchun, Chengdu, Chongqing, Fuzhou, Haโ€™erbin, Jinan, Kunming, Luoyang
2026-08-13
Not yet open
Evaluation of NWRD09 for HPV-16 Related Cervical HSIL
NCT07712692High-grade Squamous Intraepithelial Lesion (HSIL)
Newish Biotech (Wuxi) Co., Ltd.
Phase 2
156
Beijing, Chongqing, Lanzhou, Baoding, Zhengzhou, Nanjing, Changchun, Jinan
2026-08-01
Not yet open
Total Arterial vs. Mixed Grafting in Left Coronary CABG
NCT07057713Coronary Artery Disease, Coronary Artery Bypass Grafting, Arterial Graft, Graft Patency
Second Hospital of Jilin University
Not applicable
400
Changchun
2026-08-01
Not yet open
AI-assisted Rare Disease Diagnosis
NCT07650799Rare Disorders, Rare Diseases
Peking Union Medical College Hospital
Not applicable
1,056
Beijing, Cangzhou, Changchun, Dongguan, Foshan, Guiyang, Jilin City, Kunming
2026-08-01
Not yet open
A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors
NCT07787520Patients With Advanced Solid Tumors
Laekna Limited
Phase 1
150
Hefei, Beijing, Changchun, Shanghai, Hangzhou
2026-08
Not yet open
Diagnostic Accuracy and Safety of the Attention-Deficit/Hyperactivity Disorder Auxiliary Evaluation System (AHEF) in Chinese Children Aged 6 to 12
NCT07683156Attention-Deficit, Hyperactivity Disorder
Chongqing Jinsaixing Medical Technology Co., Ltd
Observational
570
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Changchun, Shanghai, Chengdu
2026-07-31
Not yet open
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
NCT07708285NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2, Vestibular Schwannoma
Beijing Tiantan Hospital
Phase 1/2
30
Beijing, Changchun, Shanghai
2026-07-31
Active, closed
Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer
NCT07806110Pancreas Ductal Adenocarcinoma
The First Hospital of Jilin University
Phase 2
62
Changchun
2026-07-30
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Luoyang
2026-07-27
Not yet open
Benson Relaxation for Anxiety and Depression After Stroke
NCT07731282Ischemic Stroke, Acute, Post-stroke Anxiety, Post-stroke Depression
Geng Nannan
Not applicable
74
Changchun
2026-07-23
Recruiting
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
NCT07596784Generalized Myasthenia Gravis, gMG
Alexion Pharmaceuticals, Inc.
Phase 3
20
Beijing, Changchun, Fuzhou, Jinan, Shanghai, Shijiazhuang, Taiyuan, Tianjin
2026-07-20
Not yet open
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
NCT07713745Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma
Beijing Tiantan Hospital
Phase 2
200
Beijing, Changchun, Shanghai
2026-07-18
Recruiting
DAREONยฎ-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)
Boehringer Ingelheim
Phase 3
390
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2026-07-10
By invitation
Establishment of a Sleep and Sleep-disorder Research Cohort in Patients With Neurological Disorders
NCT07374393Sleep, Neurology
The First Hospital of Jilin University
Observational
100
Changchun
2026-07-04
Recruiting
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
NCT07670416Obesity, Overweight, Type 2 Diabetes Mellitus (T2DM)
Hoffmann-La Roche
Phase 3
300
Zhengzhou, Xianyang, Ningbo, Beijing, Changchun, Hefei, Herbin, Huai'an
2026-07-03
Not yet open
Perioperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Grafting: A Prospective Clinical Study
NCT07650487Myocardial Injury, Coronary Artery Disease
Second Hospital of Jilin University
Observational
150
Changchun
2026-07-01
Recruiting
Application of Cardiophrenic Lymphadenectomy in Advanced Ovarian Cancer: A Single-Center Prospective Exploratory Study
NCT07572409Ovarian Cancer
manxiaxia
Not applicable
52
Changchun
2026-07-01
Recruiting
Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)
NCT07719140Childhood-onset Systemic Lupus Erythematosus, Lupus Nephritis (LN)
Peking Union Medical College Hospital
Phase 4
198
Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Changchun, Shanghai
2026-07
Not yet open
A Clinical Study of HRS-8797 in Healthy Participants
NCT07698756Atopic Dermatitis
Chengdu Suncadia Medicine Co., Ltd.
Phase 1
74
Changchun
2026-07
Recruiting
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
NCT07604766Platinum-resistant Ovarian Cancer
Genmab
Phase 3
82
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan
2026-06-26
Not yet open
Artificial Intelligence for Rare Disease Diagnosis
NCT07625436Rare Disorders, Rare Diseases
Peking Union Medical College Hospital
Not applicable
150
Beijing, Cangzhou, Changchun, Dongguan, Foshan, Guiyang, Jilin City, Kunming
2026-06-20
Not yet open
Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma
NCT07677813DLBCL - Diffuse Large B Cell Lymphoma
Ou Bai, MD/PHD
Phase 2
66
Changchun
2026-06-16
Recruiting
Full-Course ECMO Strategy for Moderate-to-Severe ARDS
NCT07726953Acute Respiratory Distress Syndrome
Southeast University, China
Not applicable
500
Beijing, Changchun, Chengdu, Chenzhou, Dalian, Fuzhou, Guangzhou, Hangzhou
2026-06-16
Recruiting
Immune Mechanisms and ECMO Strategies for Moderate-to-Severe ARDS
NCT07726940Acute Respiratory Distress Syndrome (ARDS)
Southeast University, China
Observational
1,776
Beijing, Fuzhou, Nanjing, Jinan, Chengdu, Hangzhou, Changchun, Chenzhou
2026-06-16
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Hefei, Guangzhou, Wuhan, Nanjing, Nantong, Changchun, Jinan, Yantai
2026-06-16
Not yet open
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
NCT07699770Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain
Tang-Du Hospital
Phase 4
110
Beijing, Chongqing, Harbin, Hohhot, Changchun, Shenyang, Xi'an, รœrรผmqi
2026-06-15
Not yet open
A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)
NCT07663838Randomized, Open-label, Safety, Tolerability
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
30
Beijing, Nanjing, Nanchang, Changchun, Jinan, Taiyuan, Tianjin
2026-06-15
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Lanzhou, Nanchang, Nanjing
2026-06-11
Recruiting
Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction
NCT07620041Refractory or Relapsed Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1
48
Changchun
2026-06-09
Recruiting
Two Different Endoscopic Treatments for Rectal Neuroendocrine Neoplasms
NCT07612748Rectal Neuroendocrine Tumors, ESD, EPMR
Jilin University
Not applicable
483
Changchun
2026-06-01
Not yet open
Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment
NCT07550634Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B), Hepatic Insufficiency (MeSH ID: D048550)
MindRank AI Ltd
Phase 1
32
Changchun
2026-06-01
Not yet open
Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy
NCT07627464Renal Cell Carcinoma (RCC)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
144
Beijing, Changchun, Changsha, Hangzhou, Kunming, Nanjing, Nanning, Qingdao
2026-05-31
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Chaoyang District, Chengdu, Guangzhou, Nanchang, Shenzhen, Tianjin
2026-05-31
Recruiting
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
NCT07493109Diffuse Large B-Cell Lymphoma (DLBCL)
Ou Bai, MD/PHD
Phase 3
200
Changchun
2026-05-30
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206Colorectal Cancer
AbbVie
Phase 3
990
Beijing, Guangzhou, Nanning, Wuhan, Changchun, Shenyang, Yinchuan, Jinan
2026-05-22
Not yet open
A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)
NCT07593144Advanced Solid Tumors
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1
156
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun
2026-05-15
Recruiting
Laparoscopic-endoscopic Surgery Assisted Sentinel Lymph Node Navigation Surgery for Early Gastric Cancer
NCT07615374Early Gastric Cancer
Jilin University
Not applicable
36
Changchun, Chโ€™ang-chโ€™un
2026-05-12
Recruiting
SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)
NCT07316270AF - Atrial Fibrillation, Intracranial Hemorrhage, Spontaneous
Beijing Anzhen Hospital
Not applicable
646
Hefei, Beijing, Xiamen, Harbin, Changchun, Xi'an
2026-05-06
Not yet open
Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants
NCT07550621Healthy Volunteers (HV)
MindRank AI Ltd
Phase 1
28
Changchun
2026-05-06
Active, closed
The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression
NCT07179913Depressed, Bariatric Surgery
The First Hospital of Jilin University
Phase 4
40
Changchun
2026-05-01
Not yet open
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke
NCT07483281Acute Ischemic Stroke
China-Japan Union Hospital
Not applicable
220
Changchun
2026-05-01
Not yet open
Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG
NCT06981390Coronary Artery Disease, Coronary Artery Bypass Grafting, Saphenous Vein, Dual Antiplatelet Therapy
Kexiang Liu, MD
Not applicable
300
Changchun
2026-05-01
Not yet open
Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions
NCT07582419Hepatocellular Carcinoma (HCC)
The First Hospital of Jilin University
Observational
1,424
Changchun
2026-04-30
Recruiting
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
NCT07493148Diffuse Large B-Cell Lymphoma (DLBCL)
Ou Bai, MD/PHD
Phase 2
50
Changchun
2026-04-30
Recruiting
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
NCT07571161Alzheimer Disease
Eli Lilly and Company
Phase 3
140
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei
2026-04-30
Recruiting
A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
NCT07520162Chronic Rhinosinusitis With Nasal Polyps
AstraZeneca
Phase 3
230
Beijing, Bengbu, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Foshan
2026-04-24
Recruiting
A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)
NCT07499544Chronic Hepatitis D Infection
Huahui Health
Phase 3
160
Changchun, Kashgar, รœrรผmqi
2026-04-22
Not yet open
GS1-144 in Participants With Hepatic Impairment and Healthy Female
NCT07491289Hepatic Impairment and Healthy Female
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
24
Changchun
2026-04-20
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
Boehringer Ingelheim
Phase 2
405
Beijing, Changchun, Changsha, Guangzhou, Linfen, Nanjing, Ningbo, Shanghai
2026-04-20
Recruiting
Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery
NCT07400302Mucosal Melanoma, PD-L1 Positive
The First Hospital of Jilin University
Phase 2
220
Changchun
2026-04-10
Recruiting
Phase โ…ข Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
NCT07390123IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
370
Huangshan City, Wuhu, Beijing, Zhanjiang, Changsha, Changchun, Linyi, Shanghai
2026-04-07
Recruiting
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
NCT07548177Alveolar Soft Part Sarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Beijing, Chongqing, Guangdong, Harbin, Zhengzhou, Wuhan, Changsha, Changchun
2026-04-02
Not yet open
A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell Lymphoma
NCT07525817Mature B-Cell Lymphoma
Ou Bai, MD/PHD
Observational
40
Changchun
2026-04-01
Recruiting
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
NCT07295821Lung Cancer
AstraZeneca
Phase 2
60
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin
2026-04-01
Not yet open
Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D
NCT07309380Hepatitis D, Chronic
Shanghai HEP Pharmaceutical Co., Ltd.
Phase 3
150
Changchun
2026-04
Not yet open
FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis
NCT07511309Atherosclerotic Renal Artery Stenosis, Fractional Flow Reserve, Optimal Medical Therapy, Stent Implantation
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
300
Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Changchun, Jinan
2026-03-31
Recruiting
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
NCT07493265Narcolepsy
Eisai Inc.
Phase 2
64
Beijing, Changchun, Guangdong, Guangzhou, Jinan, Nanchang, Shanghai, Zhengzhou
2026-03-26
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hutchmed
Phase 3
240
Shanghai, Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing
2026-03-20
Recruiting
A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients
NCT07446738Chronic Rhinosinusitis With Nasal Polyps
AstraZeneca
Observational
200
Changchun, Changsha, Chengdu, Guangzhou, Haikou, Kunming, Nanchang, Nanjing
2026-03-19
Recruiting
The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-preserving Surgery
NCT07369531Rectal Cancer, Surgical Anastomosis, Survival , Tumor, Anal Function
The First Hospital of Jilin University
Not applicable
520
Changchun
2026-03-18
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Zhenjiang, Xianyang, Jinan, Beijing, Changchun, Hefei, Herbin, Huizhou
2026-03-16
Not yet open
Safety and Efficacy of Remote Ischemic Conditioning in Patients With Spontaneous Intracerebral Hemorrhage
NCT03484936Intracranial Hemorrhages
Yi Yang
Not applicable
530
Changchun
2026-03-15
Recruiting
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
NCT07396584Solid Tumors, Adult
Hutchmed
Phase 1/2
186
Changchun, Changsha, Jinan, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
2026-03-04
By invitation
Research on the Impact of Gamification Movement on Children With Sensory Integration Disorders
NCT07446530Sensory Integration Dysfunction
Northeast Normal University
Not applicable
48
Changchun
2026-03-01
Recruiting
Digital Remote Management for Care and Continuous Optimization Versus Usual Care to Reduce Risk of Atherosclerotic Cardiovascular Diseases (DigiCare-preASCVD)
NCT07332468Atherosclerotic Cardiovascular Diseases
Beijing Anzhen Hospital
Not applicable
564
Beijing, Changchun, Dalian, Nanchang, Shanghai
2026-02-25
Recruiting
Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria
NCT07505472Rectal Cancer
The First Hospital of Jilin University
Phase 2/3
212
Changchun
2026-02-23
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
AstraZeneca
Phase 3
508
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing
2026-02-23
Not yet open
Effect of Individualized Catheter Management on Early Removal After Rectal Cancer Surgery
NCT07346586Urinary Catheters, Rectal Cancer, Urinary Retention
The First Hospital of Jilin University
Not applicable
1,545
Changchun
2026-02-20
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302Acute Ischemic Stroke
Boehringer Ingelheim
Phase 3
1,325
Anyang, Baoji, Baotou, Beijing, Cangzhou, Changchun, Changsha, Chengdu
2026-02-17
Recruiting
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
NCT07220083Focal Segmental Glomerulosclerosis
Boehringer Ingelheim
Phase 3
286
Baotou, Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Lanzhou
2026-02-16
By invitation
Innovative Probe With Laser on Radial Artery Puncture and Catheterisation in Paediatric
NCT07454005Radial Artery Catheterization, Paediatric, Ultrasound Guided
The First Hospital of Jilin University
Not applicable
408
Changchun
2026-02-11
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
Eli Lilly and Company
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Kunming
2026-02-10
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
Eli Lilly and Company
Phase 3
900
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou
2026-02-10
Recruiting
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
NCT07353931Osteoarthritis, Overweight or Obesity
Eli Lilly and Company
Phase 3
900
Beijing, Bengbu, Changchun, Changsha, Chongqing, Hangzhou, Hefei, Jinan
2026-02-09
Not yet open
A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study
NCT07375979Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Observational
14,300
Shijiazhuang, Zhengzhou, Changchun, Shenyang, Shanghai, Kunming
2026-02-05
Not yet open
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE๏ผ‰
NCT07274137Overweight or Obesity
MindRank AI Ltd
Phase 3
738
Beijing, Changchun, Changde, Changsha, Datong, Dongyang, Ganzhou, Hefei
2026-02
Not yet open
A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations
NCT07345689Hepatic Insufficiency, Renal Insufficiency, Elderly
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 4
60
Changchun
2026-01-30
Recruiting
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
NCT07281976Triple Negative Breast Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
220
Guangzhou, Harbin, Zhengzhou, Nanjing, Changchun, Shenyang
2026-01-27
Recruiting
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT07347600Locally Advanced Breast Cancer, Metastatic Breast Cancer
Hoffmann-La Roche
Observational
500
Xiamen, Lanzhou, Changchun, Wenzhou, Beijing, Chengdu, Chongqing, Guangzhou
2026-01-21
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
NCT07309562Small for Gestational Age
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
141
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou
2026-01-20
Recruiting
Clinical Efficacy and Health Economic Evaluation of an Intelligent Diagnostic and Treatment Model
NCT07357779Insomnia
Zan Wang
Not applicable
404
Changchun
2026-01-20
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
Boehringer Ingelheim
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan
2026-01-16
Recruiting
A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
NCT07361289Hypertrophic Cardiomyopathy
Bristol-Myers Squibb
Observational
500
Beijing, Guangzhou, Jiazhuang, Harbin, Zhengzhou, Suzhou, Changchun, Dalian
2026-01-15
By invitation
In-plane Versus Real Time Bi-plane Single-operator Laser-assisted With a Innovative T-shaped Probe for Ultrasound-guided Internal Jugular Vein Catheterization:A Randomized Controlled Trial
NCT06958731Catheterization, Central Venous, Ultrasound Guided
The First Hospital of Jilin University
Not applicable
352
Changchun
2026-01-12
Recruiting
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285Overweight, Obesity
Novo Nordisk A/S
Phase 3
460
Beijing, Zhengzhou, Wuhan, Changchun, Jinan, Shanghai, Chengdu
2026-01-08
Recruiting
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
NCT07303803MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus)
Shanghai Jiao Tong University School of Medicine
Phase 2
300
Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Shiyan, Changsha, Changchun
2026-01-01
Not yet open
Multicenter Pediatric Low-Dose CT Protocol: Development and Clinical Verification
NCT07199101Radiation Dose Reduction
Beijing Children's Hospital
Not applicable
2,650
Beijing, Chongqing, Guangzhou, Baoding, Zhengzhou, Wuxi, Changchun, Xi'an
2026-01-01
Rows per page Showing 1–100 of 641
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china/city/changchun

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 641 of those studies with a site in Changchun.

How many clinical trials are recruiting in Changchun?

330 of the 641 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 62 have not yet opened recruitment, 237 are active but closed to new participants, and 12 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Changchun), 641 studies
PhaseStudiesRecruitingShare
Phase 329013445.2%
Phase 21045316.2%
Not applicable724411.2%
Observational54328.4%
Phase 148247.5%
Phase 1/237265.8%
Phase 2/317102.7%
Phase 41772.7%
Phase EARLY_PHASE1200.3%

Most active sponsors

Lead sponsors with the most studies (Changchun)
Lead sponsorStudiesRecruiting
AstraZeneca10245
The First Hospital of Jilin University4730
Hoffmann-La Roche3113
Janssen Research & Development, LLC3011
Eli Lilly and Company2311
Novartis Pharmaceuticals2210
Daiichi Sankyo177
Boehringer Ingelheim1413
Yi Yang126
Pfizer114
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.